Europe Next Generation Sequencing Ngs Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2023 –2029 |
 시장 규모(기준 연도) |
|
 시장 규모(예측 연도) |
USD 100.35 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
>유럽 차세대 시퀀싱(NGS) 시장, 제품별(장비, 소모품 및 서비스), 응용 분야별(진단, 바이오마커 발견, 정밀 의학 , 신약 발견, 농업 및 동물 연구 및 기타), 최종 사용자별(제약 및 생명 공학 회사, 연구 센터 및 학계 및 정부 기관, 병원 및 진료소), 국가별(독일, 영국, 이탈리아, 프랑스, 스페인, 스위스, 러시아, 터키, 벨기에, 네덜란드 및 기타 유럽 국가) 산업 동향 및 2029년까지의 예측.
시장 분석 및 통찰력 : 유럽 차세대 시퀀싱(NGS) 시장
유럽 차세대 시퀀싱(NGS) 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 15.7%의 CAGR로 성장하고 있으며 2029년까지 8,733.08백만 달러에 도달할 것으로 예상된다고 분석했습니다. 차세대 시퀀싱에 대한 연구 활동의 증가는 차세대 시퀀싱(NGS) 시장 성장을 촉진하는 요인으로 작용합니다.
"차세대" 시퀀싱(NGS)으로 가장 널리 알려진 고처리량 시퀀싱은 수많은 기술적, 기능적 개발로 인해 이제 일상적인 임상 실무에 통합되었지만, 초기 프로토콜은 임상 병리학의 일반적인 워크플로 외부에서 수집된 샘플, 표준 포르말린 고정, 파라핀 포매 표본에 의존했으며, 이는 NGS의 시작 재료로 보다 정기적으로 사용될 수 있습니다. 또한 NGS 데이터의 분석 및 해석과 지식 기반을 위한 프로토콜이 수집되고 있어 임상의가 환자 치료 지점에서 게놈 정보에 대해 보다 쉽게 조치를 취할 수 있습니다. 만성 질환 진단에 사용되는 차세대 시퀀싱의 광범위한 제품이 존재하여 의료 시설의 요구를 충족시키고 있습니다. 증가된 기술 발전으로 인해 시장에서 고효율 차세대 시퀀싱(NGS)이 개발되고 있습니다.
차세대 시퀀싱(NGS) 시장 성장을 견인하는 주요 요인은 약물 개발에 있어서 차세대 시퀀싱을 활용하는 것과 주요 기업이 제공하는 폭넓은 포트폴리오입니다. 차세대 시퀀싱(NGS) 시장 성장을 방해하는 요인으로는 차세대 시퀀싱 제품의 높은 비용과 제품 리콜이 있습니다.
차세대 시퀀싱(NGS) 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 창출, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 차세대 시퀀싱(NGS) 시장 시나리오를 이해하려면 Data Bridge Market Research에 연락하여 분석가 브리핑을 요청하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.
Next Generation Sequencing (NGS) Market Scope and Market Size
The next generation sequencing (NGS) market is segmented on basis of product, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Europe next generation sequencing (NGS) market is segmented into instrument, consumables, and services. In 2022, the instrument segment is expected to dominate the Europe next generation sequencing (NGS) market as the instruments as the presence of wide instrument portfolio available for the European countries and this is also the major segment contributing to the revenue.
- On the basis of application, the Europe next generation sequencing (NGS) market is segmented into diagnostic, drug discovery, biomarker discovery, precision medicine, agriculture and animal research. In 2022, the diagnostic segment is expected to dominate Europe next generation sequencing (NGS) market due to the fact that clinical laboratories and laboratories are using NGS for routine diagnosis of various disease because it has the potential to deliver precise test result and provide excellent treatment regime.
- On the basis of end user, the Europe next generation sequencing (NGS) market is segmented into hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies. In 2022, research center and academic & government institutes is expected to dominate the Europe next generation sequencing (NGS) market as the European countries are known to have advance research institutes which are constantly working on NGS with collaboration with Pharma companies,
Next Generation Sequencing (NGS) Market Country Level Analysis
The next generation sequencing (NGS) market is analyzed and market size information is provided by the country, product, application and end user as referenced above.
The countries covered in the next generation sequencing (NGS) market report are the U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Austria, Ireland, and Rest of Europe.
Research centers and academic & government institutes segment in Germany of European region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of NGS in these centers where the ground level research is performed.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Next Generation Sequencing (NGS) Treatment, is Boosting the Market Growth of Next Generation Sequencing (NGS) Market
The next generation sequencing (NGS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Next Generation Sequencing (NGS) Market Share Analysis
Next generation sequencing (NGS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induce next generation sequencing (NGS) market.
Some of the major companies which are dealing in the next generation sequencing (NGS) are Agilent Technologies, Inc., ThermoFisher Scientific, Inc., QIAGEN, Illumina, Inc., Bio-Rad Laboratories, Inc., BGI (A subsidiary of BGI Group), Oxford Nanopore Technologies plc, among others domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the next generation sequencing (NGS) market.
For instance,
- In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in Europe market and leading to upsurge Company’s growth in the coming years.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략을 통해 차세대 시퀀싱(NGS) 시장에서 회사의 입지를 강화하고 조직의 수익 성장에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL'S ANALYSIS
3.2 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENT
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS
5.2.3 CYBER SECURITY CONCERN IN GENOMICS
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
5.3.2 PRODUCT APPROVAL IN RECENT YEARS
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY
5.4 CHALLENGES
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB
6 IMPACT OF COVID-19 ON EUROPE NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY
6.1 IMPACT ON PRICE
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 HISEQ SERIES
7.2.2 MISEQ SERIES
7.2.3 ION TORRENT
7.2.4 PACBIO RS II
7.2.5 SEQUEL SYSTEM
7.2.6 SOLID
7.2.7 OTHERS
7.3 CONSUMABLE
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
7.3.2 SAMPLE PREPARATION CONSUMABLES
7.3.3 OTHERS
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DATA MANAGEMENT
8 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 BIOMARKER DISCOVERY
8.4 PRECISION MEDICINE
8.5 DRUG DISCOVERY
8.6 AGRICULTURE & ANIMAL RESEARCH
9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES
9.4 HOSPITAL & CLINICS
10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
10.1 EUROPE
10.1.1 GERMANY
10.1.2 FRANCE
10.1.3 U.K.
10.1.4 ITALY
10.1.5 RUSSIA
10.1.6 SPAIN
10.1.7 SWITZERLAND
10.1.8 NETHERLANDS
10.1.9 BELGIUM
10.1.10 TURKEY
10.1.11 REST OF EUROPE
11 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 COMPANY PROFILING
12.1 ILLUMINA, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 SWOT ANALYSIS
12.1.5 PRODUCT PORTFOLIO
12.1.6 RECENT DEVELOPMENTS
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 SWOT ANALYSIS
12.2.5 PRODUCT PORTFOLIO
12.2.6 RECENT DEVELOPMENT
12.3 THERMO FISHER SCIENTIFIC INC.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 SWOT ANALYSIS
12.3.5 PRODUCT PORTFOLIO
12.3.6 RECENT DEVELOPMENTS
12.4 QIAGEN
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 SWOT ANALYSIS
12.4.5 PRODUCT PORTFOLIO
12.4.6 RECENT DEVELOPMENTS
12.5 AGILENT TECHNOLOGIES, INC.
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 COMPANY SHARE ANALYSIS
12.5.4 SWOT ANALYSIS
12.5.5 PRODUCT PORTFOLIO
12.5.6 RECENT DEVELOPMENT
12.6 OXFORD NANOPORE TECHNOLOGIES
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENTS
12.7 BIO-RAD LABORATORIES, INC.
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8X GENOMICS
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMÉRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.1 DNASTAR
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 GENEIOUS
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENTS
12.13 HAMILTON COMPANY
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENT
12.14 MACROGEN, INC.
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENT
12.15 NEW ENGLAND BIOLABS
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 PARTEK, INCORPORATED
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENT
12.18 PERKIN ELMER INC. (2021)
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS (PARENT COMPANY)
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENTS
12.2 TAKARA BIO INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
표 목록
TABLE 1 NEXT GENERATION SEQUENCING COST PER SAMPLE
TABLE 2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE DRUG DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE AGRICULTURE & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE HOSPITAL & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 21 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 22 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 23 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 24 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 GERMANY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 28 GERMANY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 29 GERMANY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 30 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 FRANCE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 34 FRANCE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 35 FRANCE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 36 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 37 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 39 U.K. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 40 U.K. CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 U.K. SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 45 ITALY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 46 ITALY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 47 ITALY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 48 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 RUSSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 RUSSIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 53 RUSSIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 SPAINSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 58 SPAIN CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 59 SPAIN SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 63 SWITZERLAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 64 SWITZERLAND CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 65 SWITZERLAND SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 66 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 NETHERLANDS INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 70 NETHERLANDS CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 NETHERLANDS SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 BELGIUM INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 76 BELGIUM CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 77 BELGIUM SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 78 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 79 BRLGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 TURKEY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 TURKEY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 83 TURKEY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 86 REST OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING
FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT
FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.
FIGURE 17 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021
FIGURE 18 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 19 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 20 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021
FIGURE 22 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021
FIGURE 26 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)
FIGURE 30 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)
FIGURE 31 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)
FIGURE 34 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
